Abstract:
:Central arterial systolic blood pressure is a very important factor in the pathophysiology of cardiovascular diseases. Central arterial pressure is a better predictor of cardiovascular risk than peripheral brachial blood pressure. Measurement of central blood pressure is useful for a diagnosis of spurious systolic hypertension in young people. Antihypertensive drugs have a different impact on central blood pressure, for example angiotensin converting enzyme inhibitors, antagonists of angiotensin II receptors, calcium channel blockers more effectively lower central blood pressure than betablockers, despite all of those drugs (including beta-blockers) having a similar impact on peripheral pressure. This mechanism may be responsible for the beneficial effect of some antihypertensive drugs on cardiovascular end points observed in clinical trials, despite a low peripheral hypotensive effect. However, further clinical trials are required to provide more evidence for the prognostic and therapeutic implications of the measurement of central blood pressure before adopting its routine application in clinical practice.
journal_name
Curr Vasc Pharmacoljournal_title
Current vascular pharmacologyauthors
Stepień M,Banach M,Jankowski P,Rysz Jdoi
10.2174/157016110793563852subject
Has Abstractpub_date
2010-11-01 00:00:00pages
747-52issue
6eissn
1570-1611issn
1875-6212pii
BSP/CVP/E-Pub/000096journal_volume
8pub_type
杂志文章,评审abstract::Matrix metalloproteinases (MMP) comprise a family of at least 25 zinc-dependent endopeptidases that play a pivotal role in the physiopathology of the mammalian central nervous system. In the first phases after stroke, the dysregulation of MMPs has been described to increase acute neurovascular disruption and cerebral ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/15701611113116660161
更新日期:2015-01-01 00:00:00
abstract::In the last decade there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VA) and Sudden Cardiac Death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10-15% of SCD occurs in the presence of structurally ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016109788340794
更新日期:2009-07-01 00:00:00
abstract::The incidence of cardiovascular disease is low in healthy premenopausal women and increases with age especially after the menopause; this difference has been attributed to the loss of endogenous estrogen. Atherosclerosis is a chronic inflammatory condition of the vascular wall that may result in an acute clinical even...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016110790886974
更新日期:2010-03-01 00:00:00
abstract::The hypothesis of 'Developmental Origins of Health and Disease' (DOHaD) relies on the presence of mechanisms sensing and signalling a diversity of stimuli during fetal development. The mechanisms that have been broadly suggested to be involved in these processes are the epigenetic modifications that could 'record' per...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016109789043883
更新日期:2009-10-01 00:00:00
abstract::Normal pregnancy is associated with increased insulin resistance as a metabolic adaptation to the nutritional demands of the placenta and fetus, and this is amplified in obese mothers. Insulin resistance is normally compensated for by an adaptive increase in pancreatic β-cell mass together with enhanced glucose-stimul...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161118666200320111209
更新日期:2021-01-01 00:00:00
abstract::Obesity and Gestational Diabetes Mellitus (GDM) are the most frequent pathologies affecting mothers and offspring during pregnancy. Both conditions have shown a sustained increase in their prevalence in recent years, and they worsen the outcome of pregnancy and the long-term health of mothers. Obesity increases the ri...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161118666200628142353
更新日期:2021-01-01 00:00:00
abstract::Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016110792006923
更新日期:2010-09-01 00:00:00
abstract::Although hypertension, hypercholesterolemia and diabetes mellitus (DM) are recognized as major cardio-metabolic risk factors in primary Acute Coronary Syndrome (ACS) prevention, studies focusing on secondary ACS incidence are scarce. In the present study, the association between the aforementioned factors and 10-year ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161113666150916093451
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:Volatile Anaesthetics (VA) are commonly used worldwide for induction and/or maintenance of general anaesthesia. They act in the central nervous system to reduce sensation and motor response during surgical and invasive diagnostic procedures. VAs also have some non-anaesthetic properties in the brain when adm...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161115666171013153750
更新日期:2018-01-01 00:00:00
abstract::During the last decades survival has significantly improved and centenarians are becoming a fast-growing group of the population. Human life span is mainly dependent on environmental and genetic factors. Favourable modifications of lifestyle factors (e.g. physical activity, diet and not smoking) and healthcare (e.g. e...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161111666131219095114
更新日期:2014-01-01 00:00:00
abstract::Cardiovascular disease (CVD) is among the most major causes of morbidity and mortality worldwide. Great progress has been made in the management of CVD which has been influenced by the use of experimental animal models. These models provided information at cellular and molecular levels and allowed the development of t...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161113666150212151506
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Add-on therapy with the Mineralocorticoid-Receptor-Antagonists (MRAs) spironolactone and eplerenone was shown to enhance the cardioprotective action of angiotensinconverting- enzyme-inhibitors (ACEIs), angiotensin-receptor-blockers (ARBs) and/or β-blockers in nondialysis patients with congestive heart failur...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161115666170201113817
更新日期:2017-01-01 00:00:00
abstract::This paper provides an overview of the pathogenesis, presentation and diagnosis of clopidogrel hypersensitivity. The majority of clopidogrel hypersensitivity cases are due to a T cell mediated Gell and Coombs Type IV reaction. History, histology, and patch testing have shown consistency with a T cell mediated mechanis...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161116666181031143628
更新日期:2019-01-01 00:00:00
abstract::High density lipoprotein (HDL) is recognized as the major negative risk factor of cardiovascular disease and number of anti-atherogenic functions has been ascribed to HDL. HDL is an assembly of a neutral lipid core and an outer shell consisting of polar lipids and proteins. It has been defined many different ways base...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016112800812755
更新日期:2012-07-01 00:00:00
abstract::The "pleiotropic" effects of statins have been the centre of a considerable research activity. Among the numerous experimental and clinical studies of this field, some focused on the effects of statins on blood pressure (BP), while others reported data on BP together with other parameters. Some of the animal or human ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016107780368307
更新日期:2007-04-01 00:00:00
abstract::In end-stage renal disease patients, the leading causes of mortality are of cardiovascular (CV) origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. A contributing role of oxidative stress is postulated, which is increased even at early stages ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161118666200317151553
更新日期:2021-01-01 00:00:00
abstract:: ...
journal_title:Current vascular pharmacology
pub_type: 社论
doi:10.2174/1570161116666180713120217
更新日期:2019-01-01 00:00:00
abstract::Paraoxonase-1 (PON-1) is a calcium-dependent enzyme that is synthesized in the liver and then secreted in blood where it is bound to high density lipoprotein (HDL). PON-1 is a hydrolase with a wide range of substrates, including lipid peroxides. It is considered responsible for many of the antiatherogenic properties o...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161115666171129212359
更新日期:2019-01-01 00:00:00
abstract::Obesity is a risk factor for complications of atherosclerotic vascular disease such as myocardial infarction and stroke. Recent studies have demonstrated that the vascular risk associated with obesity is correlated particularly with visceral adiposity. These clinical observations indicate that various adipose tissue d...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016109787455680
更新日期:2009-04-01 00:00:00
abstract::Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulat...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016110790226679
更新日期:2010-01-01 00:00:00
abstract::There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161112666140613115813
更新日期:2014-01-01 00:00:00
abstract::High blood pressure (BP) along with smoking habit and lipid disorders are the most important and modifiable risk factors for cardiovascular diseases. However, the prevalence of high BP has grown progressively over time with a progressive increase not only in the absolute number of patients but in the proportion of tho...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016112803520927
更新日期:2012-11-01 00:00:00
abstract::Nowadays long-term outcome of heart transplantation is limited by a peculiar type of coronary atherosclerosis, known as cardiac allograft vasculopathy (CAV). Although the exact pathogenesis of CAV remains unclear, emerging evidence indicates that the endothelium plays a significant role in the onset and progression of...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016110790886992
更新日期:2010-03-01 00:00:00
abstract:BACKGROUND:In the era of dual antiplatelet therapy of aspirin and clopidogrel and systematic stent implantation, Glycoprotein IIb/IIIa Inhibitors (GPI), including abciximab, eptifibatide and tirofiban, proved beneficial in improving early outcome of Percutaneous Coronary Intervention (PCI), especially in higher risk cl...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161116666180117102422
更新日期:2018-01-01 00:00:00
abstract::Fifteen years after its discovery, NO has fully reached an established position in physiology, medicine and therapeutics. It is difficult to find a biological function or a pathological condition where NO does not play a relevant role. Discoveries in the NO field have historically evolved from cardiovascular research,...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161033476637
更新日期:2003-10-01 00:00:00
abstract::High-mobility group box-1 (HMGB1) is a nuclear protein that acts as a cytokine when released into the extracellular milieu by necrotic and inflammatory cells, and is involved in inflammatory responses and tissue repair. This protein is released passively during cellular necrosis by almost all cells that have a nucleus...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016111797484125
更新日期:2011-11-01 00:00:00
abstract::Monoclonal antibodies have been developed to optimize treatment effects in various malignant and nonmalignant conditions, by selectively targeting key components of the underlying pathophysiologic processes. Rituximab, a chimeric anti-CD20 antibody has revolutionized treatment of malignant lymphomas, extending remissi...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016110790226651
更新日期:2010-01-01 00:00:00
abstract::This review considers drug combinations and newer treatment strategies for patients with severe hypertriglyceridemia. Hypertriglyceridemia is associated with an atherogenic metabolic profile and in most studies with increased cardiovascular disease risk. Patients with severe hypertriglyceridemia also have increased in...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/15701611113119990133
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:The primary objective of this study was to evaluate the impact of polypharmacy on primary and secondary adherence to evidence-based medication (EBM) and to measure factors associated with non-adherence among patients who underwent percutaneous coronary intervention (PCI). METHODS:We conducted a retrospectiv...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161113666151030105805
更新日期:2016-01-01 00:00:00
abstract::In patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), 25OH-vitamin D (calcidiol) deficiency or insufficiency is a common finding with high prevalence. Numerous epidemiological studies have found an independent association of low levels of calcidiol with increased morbidity and mortality. Wi...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/15701611113119990027
更新日期:2014-03-01 00:00:00